Overview

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Status:
Not yet recruiting

Trial end date:
2035-07-01

Target enrollment:

Participant gender:

Summary

This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.

Phase:

Phase 2

Details

Lead Sponsor:

St. Jude Children's Research Hospital

Treatments:

Carboplatin
Cyclophosphamide
Etoposide
Methotrexate
Topotecan
Vincristine